• Home
  •  / Johnson & Johnson

Johnson & Johnson

OverviewSuggest Edit

Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three business segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment is focused on the therapeutic areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolism, as well as pulmonary hypertension. The Medical Devices segment includes a broad range of products used in the orthopedic, surgery, interventional solutions, and eye health fields.

Its major brands include: 

TypePublic
Founded1886
HQNew Brunswick, USMap
Websitejnj.com
Employee Ratings4More
Culture scoreA-More
View Jobs (618)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)132,200(-2%)
Job Openings618
Revenue (FY, 2019)$82.1 B
Share Price (May 2020)$144.4 (-1%)

Key People/Management at Johnson & Johnson

Alex Gorsky

Alex Gorsky

Chairman, Board of Directors and Chief Executive Officer
Joaquin Duato

Joaquin Duato

Vice Chairman of the Executive Committee
Ashley McEvoy

Ashley McEvoy

Executive Vice President, Worldwide Chairman, Medical Devices
Peter Fasolo

Peter Fasolo

Executive Vice President, Chief Human Resources Officer
Thibaut Mongon

Thibaut Mongon

Executive Vice President, Worldwide Chairman, Consumer Health
Paul Stoffels

Paul Stoffels

Vice Chairman of the Executive Committee and Chief Scientific Officer
Show more

Johnson & Johnson Office Locations

Johnson & Johnson has offices in New Brunswick, Jacksonville, Lancaster, Piscataway and in 67 other locations
New Brunswick, US (HQ)
1 Johnson And Johnson Plaza
Jacksonville, US
7500 Centurion Pkwy N
Lancaster, US
1838 Colonial Village Ln
Piscataway, US
425 NJ-18
Buenos Aires, AR
Mendoza 1259
Yerevan, AM
3 Building, 4th Floor, 70 Dzorapi St
Show all (74)

Johnson & Johnson Financials and Metrics

Johnson & Johnson Revenue

Embed Graph
View revenue for all periods
Johnson & Johnson's revenue was reported to be $82.06 b in FY, 2019 which is a 0.6% increase from the previous period.
USD

Revenue (FY, 2019)

82.1b

Revenue growth (FY, 2018 - FY, 2019), %

0.6%

Gross profit (FY, 2019)

54.5b

Gross profit margin (FY, 2019), %

66.4%

Net income (FY, 2019)

15.1b

Market capitalization (22-May-2020)

380.4b

Closing stock price (22-May-2020)

144.4

Cash (29-Dec-2019)

17.3b

EV

390.7b
Johnson & Johnson's current market capitalization is $380.4 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

71.9b76.5b81.6b82.1b

Revenue growth, %

3%6%7%1%

Cost of goods sold

21.7b25.4b27.1b27.6b

Gross profit

50.2b51.1b54.5b54.5b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

17.8b18.8b19.7b20.0b20.8b20.3b20.0b20.6b20.7b

Cost of goods sold

5.4b5.8b6.9b6.6b6.9b6.6b6.6b6.9b6.9b

Gross profit

12.4b13.0b12.7b13.4b13.9b13.8b13.4b13.6b13.9b

Gross profit Margin, %

70%69%65%67%67%68%67%66%67%
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

19.0b17.8b18.1b17.3b

Accounts Receivable

11.7b13.5b14.1b14.5b

Prepaid Expenses

3.3b2.5b2.7b2.4b

Inventories

8.1b8.8b8.6b9.0b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

20.9b12.6b15.7b14.6b17.6b16.1b14.7b14.4b16.2b

Accounts Receivable

12.3b13.3b13.2b14.2b14.1b14.0b14.1b14.7b14.8b

Prepaid Expenses

2.8b3.0b2.9b2.6b2.6b2.9b2.6b2.4b2.2b

Inventories

8.9b9.7b9.5b9.0b8.8b8.7b9.1b9.3b9.2b
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

16.5b1.3b15.3b15.1b

Depreciation and Amortization

3.8b5.6b6.9b7.0b

Inventories

(249.0m)581.0m(644.0m)(277.0m)

Accounts Payable

656.0m2.7b4.0b4.1b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

4.4b8.2b12.0b4.4b8.3b12.3b3.7b9.4b11.1b

Depreciation and Amortization

912.0m2.1b3.8b1.7b3.5b5.2b1.8b3.5b5.2b

Inventories

(368.0m)(421.0m)(193.0m)(322.0m)(491.0m)(777.0m)(369.0m)(423.0m)(424.0m)

Accounts Payable

(2.0b)(1.2b)339.0m(1.7b)(49.0m)731.0m(1.8b)(444.0m)2.3b
show all
USDY, 2019

EV/CFO

16.7 x

Revenue/Employee

620.7k

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2.7 x

P/E Ratio

25.6
Show all financial metrics

Johnson & Johnson Operating Metrics

FY, 2016FY, 2017Jun, 2018FY, 2018FY, 2019

Manufacturing Facilities

119 125 111 97

Countries

60 60 60

Distribution Centers

350

Suppliers

3.50 k
Show all operating metrics

Johnson & Johnson Acquisitions / Subsidiaries

Company NameDateDeal Size
TARIS BiomedicalDecember 20, 2019
Verb SurgicalDecember 20, 2019
Auris HealthJanuary 23, 2019$3.40 b
Ci:z HoldingsOctober 23, 2018$2.10 b
Zarbee's NaturalsJuly 27, 2018
OrthotaxyFebruary 20, 2018
Actelion PharmaceuticalsJanuary 26, 2017$30 b
Abott Medical OpticsSeptember 16, 2016$4.33 b
Vogue InternationalJune 02, 2016$3.30 b
Novira TherapeuticsNovember 08, 2015
Show more

Johnson & Johnson Revenue Breakdown

Embed Graph

Johnson & Johnson revenue breakdown by business segment: 31.6% from Medical Devices, 51.4% from Pharmaceutical and 16.9% from Consumer

Johnson & Johnson revenue breakdown by geographic segment: 19.0% from Asia-Pacific, Africa, 7.2% from Western Hemisphere excluding US, 22.5% from Europe and 51.3% from United States

Human Capital Metrics

Embed Graph
Show all human capital metrics

Johnson & Johnson Online and Social Media Presence

Johnson & Johnson's Trends

Embed Graph

Johnson & Johnson Company Culture

  • Overall Culture

    A-

    74/100

  • CEO Rating

    A

    76/100

  • Compensation

    B+

    74/100

  • Diversity

    A+

    79/100

Learn more on Comparably

Johnson & Johnson News and Updates

May 20, 2020

Johnson & Johnson to stop selling talc baby powder in U.S. and Canada

Johnson & Johnson on Tuesday announced it would stop selling its talc Baby Powder in the United States and Canada, saying demand had dropped in the wake of what it called "misinformation" about the product’s safety amid a barrage of legal challenges.
May 19, 2020

Stocks making the biggest moves after hours: Urban Outfitters, Moderna, Johnson & Johnson and more

Check out the companies making headlines after the bell.
April 14, 2020

Johnson & Johnson board approves quarterly dividend increase of 6.3% to $1.01 a share

Johnson & Johnson said Tuesday its board has approved a 6.3% increase in its quarterly dividend to $1.01 a share. The new dividend will be payable June 9 to shareholders of record as of May 26. Shares rose 2.3% premarket, but are down 4.2% in the year to date, while the Dow Jones Industrial Ave…
March 31, 2020

Johnson & Johnson partners with BARDA to fund $1 billion in COVID-19 vaccine research

Pharmaceutical giant Johnson & Johnson is partnering with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services to fund over $1 billion in COVID-19 vaccine and antiviral treatment research and development, the company said on Monday. The p…
March 30, 2020

Johnson & Johnson shares up after it strikes $1bn coronavirus vaccine deal

Shares in pharmaceutical giant Johnson & Johnson rose today after it said it had agreed a $1bn (£810m) deal to The post Johnson & Johnson shares rise after it strikes $1bn coronavirus vaccine deal with US government appeared first on CityAM.
March 30, 2020

The U.S. Just Signed A $450 Million Coronavirus Vaccine Contract With Johnson & Johnson

The largest reported contract for a coronavirus vaccine has gone to a pharma giant that’s yet to start clinical trials
Show more

Johnson & Johnson Blogs

May 11, 2020

Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation

Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation Liz.McPherson@… Mon, 05/11/2020 - 08:12 Biosense Webster Unveils Late-Breaking Results from PRECEPT Study in Patients with Persistent Atrial Fibrillation …
May 01, 2020

U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma

April 30, 2020

CHMP Grants Positive Opinion for DARZALEX®▼(daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

CHMP Grants Positive Opinion for DARZALEX®▼(daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma Liz.McPherson@… Thu, 04/30/2020 - 15:48 CHMP Grants Positive Opinion for DARZALEX®▼(daratumumab) Subcutaneous Formulation for the Treatment of Patients with…
April 27, 2020

Federal Judge Excludes Certain Plaintiff Expert Testimony from Talc Ovarian Cancer Trials, Deeming Them Not Scientifically Sound

Federal Judge Excludes Certain Plaintiff Expert Testimony from Talc Ovarian Cancer Trials, Deeming Them Not Scientifically Sound Liz.McPherson@… Mon, 04/27/2020 - 18:45 Federal Judge Excludes Certain Plaintiff Expert Testimony from Talc Ovarian Cancer Trials, Deeming Them Not Scientificall…
January 23, 2020

The European Commission Approves Expanded Use Of JANSSEN’S STELARA® (USTEKINUMAB) For The Treatment Of Paediatric Patients With Moderate To Severe Plaque Psoriasis

The European Commission Approves Expanded Use Of JANSSEN’S STELARA® (USTEKINUMAB) For The Treatment Of Paediatric Patients With Moderate To Severe Plaque Psoriasis Kerry.Russell@… Thu, 01/23/2020 - 11:10 The European Commission Approves Expanded Use Of JANSSEN’S STELARA® (USTEKINUMAB) For …
January 02, 2020

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020 Kerry.Russell@… Thu, 01/02/2020 - 06:45 Johnson & Johnson Announces Quarterly Dividend for First Quarter 2020 Jan 02, 2020 This release is a backfill from a News Wi…
Show more

 Johnson & Johnson Frequently Asked Questions

  • When was Johnson & Johnson founded?

    Johnson & Johnson was founded in 1886.

  • Who are Johnson & Johnson key executives?

    Johnson & Johnson's key executives are Alex Gorsky, Joaquin Duato and Ashley McEvoy.

  • How many employees does Johnson & Johnson have?

    Johnson & Johnson has 132,200 employees.

  • What is Johnson & Johnson revenue?

    Latest Johnson & Johnson annual revenue is $82.1 b.

  • What is Johnson & Johnson revenue per employee?

    Latest Johnson & Johnson revenue per employee is $620.7 k.

  • Who are Johnson & Johnson competitors?

    Competitors of Johnson & Johnson include Bayer, Pfizer and Procter & Gamble.

  • Where is Johnson & Johnson headquarters?

    Johnson & Johnson headquarters is located at 1 Johnson And Johnson Plaza, New Brunswick.

  • Where are Johnson & Johnson offices?

    Johnson & Johnson has offices in New Brunswick, Jacksonville, Lancaster, Piscataway and in 67 other locations.

  • How many offices does Johnson & Johnson have?

    Johnson & Johnson has 74 offices.